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NK cells play a crucial role in the control 
of many viruses (1, 2). The recognition of 
 virus-infected cells by NK cells is regulated 
by the balance of signaling via inhibitory and 
stimulatory receptors (1, 3). NKG2D is a 
 dominant activating NK cell receptor involved 
in  immune responses to viruses (3). It is also 
 expressed by activated CD8+ T cells, subsets 
of γδ T cells, and NK1.1+ T cells (4). Several 
mouse NKG2D ligands can be distinguished 
as follows: murine UL16-binding protein like 
transcript (MULT)-1 (5), the minor histocom-
patibility antigen H60 (6), and the retinoic acid 
early inducible (RAE)-1 isoforms (7). Both 
 human cytomegalovirus (HCMV) and mouse 
cytomegalovirus (MCMV) encode proteins that 
negatively regulate the cell surface  expression 
of NKG2D ligands and thus compromise the 
effi  cacy of NK and T cell responses (2). Among 
the members of the MCMV m145 gene family, 
the m152-encoded gp40 serves as a  modulator 
of the RAE-1 family of NKG2D ligands 
(8, 9). The product of the MCMV m155 gene 
down-modulates H60 (10, 11), whereas the 
m145-encoded protein aff ects the expression of 
MULT-1 (12).
Members of the α- and β-subfamily of the 
herpesviruses encode transmembrane glyco-
proteins that selectively bind IgG via its Fc 
 domain. The viral Fcγ receptors (vFcγRs) 
are expressed on the surface of infected cells 
(13, 14). According to the model of “antibody 
bipolar bridging,” the IgG molecule that rec-
ognizes an epitope on an infected cell is se-
questered via its Fc part by vFcγR. Thus, the 
engagement of the IgG Fc domain may pre-
vent antiviral eff ector activities such as the trig-
gering of NK cells via cellular FcγRs and the 
activation of its complement. MCMV ex-
presses a vFcγR encoded by the m138/fcr-1 
gene (15). Deletion of this gene results in a 
dramatic virus attenuation in vivo irrespective 
of the presence of antibodies, suggesting that 
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the observed phenotype is not only dependent on the fcr-1 
property to bind IgG (16).
A detailed comparison of the eff ects of WT and mutant 
MCMV infections on cellular H60 expression level  suggested 
the presence of an additional m155 independent inhibitory 
function encoded by MCMV genome (8, 10). Furthermore, 
the up-regulation of MULT-1 mRNA and only a modest 
up-regulation of surface MULT-1 on cells infected with 
∆m145 virus also opened the possibility for an additional 
 viral inhibitor of MULT-1 (12). Systematic analysis of 
MCMV deletion mutants guided our search to a single gene, 
m138/fcr-1, as a causal principle, being able to down-modulate 
both NKG2D ligands. This fi nding provides an explana-
tion for the IgG-independent attenuation of ∆m138/fcr-1 
MCMV and demonstrates novel immune-evasive functions 
of viral FcγR.
RESULTS AND D I S C U S S I O N 
MCMV down-modulation of NKG2D ligands requires fcr-1
The MCMV m155 and m145 gene products prevent the 
 surface expression of H60 and MULT-1 on MCMV-infected 
cells, respectively (10, 12). However, the deletion of these 
genes from MCMV genome could not fully explain H60 and 
MULT-1 down-regulation. This prompted us to continue 
in vitro screening for additional inhibitors using MCMV 
 mutants lacking diff erent sets of nonessential genes. NIH3T3 
cells were infected with mutant MCMVs and analyzed for 
surface density of NKG2D ligands using a NKG2D tetramer. 
As controls, WT MCMV and the mutant virus ∆6 lacking 
most of the m145 gene family members including m145, 
m152, and m155 were used. In line with previous results (8, 
10), the infection with WT MCMV resulted in a strong 
down-modulation of NKG2D ligands, whereas cells infected 
Figure 1. Selective down-modulation of NKG2D ligands MULT-1 
and H60 by MCMV fcr-1. 12 h p.i., NIH3T3 cells were analyzed for the 
expression of NKG2D ligands using the NKG2D-PE tetramer (a), whereas 
SVEC4-10 cells were stained for the expression of MULT-1 with rat anti–
MULT-1 mAb (b) or with F(ab)2 fragments of rat anti–MULT-1 mAb (c) 
followed by anti–rat-PE. H60-3T3 cells were stained 16 h p.i. with rat 
anti-H60 mAb followed by anti–rat-FITC (d). 12 h p.i. B12 cells were 
stained with anti-RAE–1αβγ mAb (e) or anti–H-2Kd mAb (f) followed by 
FITC-labeled secondary Ab. Irrelevant primary mAbs were used as a nega-
tive control (thin line). Infection was performed with 1 PFU per cell of 
indicated viruses.
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with ∆6 virus remained positive (Fig. 1 a). Interestingly, the 
infection with ∆A1 MCMV mutant lacking the gene region 
m128 through m138 also preserved NKG2D ligand expression. 
Because the gene encoding the MCMV receptor for the 
Fc fragment of IgG, m138/fcr-1 is located in this region, we 
examined whether this protein might be involved. Indeed, 
two independent mutants possessing only the deletion of 
m138/fcr-1 gene were unable to down-regulate NKG2D 
 ligands to the level of WT MCMV (Fig. 1 a). Next, we 
 analyzed which of the NKG2D ligands are regulated by 
m138/fcr-1. The specifi c down-modulation of MULT-1 by 
fcr-1 was demonstrated because all three viral mutants  lacking 
m138/fcr-1 were unable to aff ect its surface expression (Fig. 1 b). 
In contrast, the m138/fcr-1 revertant virus (RMS95.9) was 
able to down-modulate surface MULT-1. The possibility 
that fcr-1 caused down-modulation of surface MULT-1 
 relating to its ability to bind IgG via the Fc domain (15) was 
ruled out by the use of F(ab)2 fragments of anti–MULT-1 
mAb (Fig. 1 c). Experiments performed with H60-3T3 
 transfectants revealed that the surface expression of H60 is 
also regulated by m138/fcr-1, although not as effi  ciently as in 
the case of MULT-1 (Fig. 1 d). To assess the specifi city of the 
fcr-1 interaction with potential targets, surface expression of 
RAE-1αβγ ligands of the NKG2D receptor and the MHC 
class I allele H-2Kd was analyzed. The cells were infected 
with WT MCMV, ∆m138/fcr-1, ∆m152, and the virus strain 
lacking m06 in addition to m152. The down-modulation of 
RAE-1 (Fig. 1 e) and MHC class I H-2Kd (Fig. 1 f) turned 
out to be independent of the presence or absence of fcr-1. 
Altogether, the data established that fcr-1 selectively down-
modulates expression of NKG2D ligands MULT-1 and H60 
on the surface of infected cells.
Down-modulation of NKG2D ligands by fcr-1 
is independent of other viral proteins
The MCMV m145- and m155-encoded glycoproteins have 
been demonstrated to act as autonomous inhibitors of 
MULT-1 and H60, respectively. To test whether fcr-1 can 
also inhibit MULT-1 and H60 on its own or if it requires 
MCMV coregulators, recombinant Vaccinia viruses (VV) ex-
pressing fcr-1, MULT-1, and H60 were used (Fig. 2 a). CV1 
cells infected with MULT-1–VV showed a high expression 
Figure 2. fcr-1 is effi cient both in vivo and in isolated in vitro 
conditions. (a) CV-1 cells infected with indicated Vaccinia viruses for 
16 h or (b) HEK 293T cells cotransfected with indicated plasmids for 
24 h were analyzed for the expression of MULT-1 or H60. Irrelevant pri-
mary mAbs were used as a negative control (thin line). NK cell–depleted 
or undepleted BALB/c mice were injected i.v. with (c) 2 × 105 PFU of 
indicated viruses or (d) 104 BALB/c MEF cells were infected for 12 h 
with 2 PFU of indicated viruses. (e) Untreated BALB/c mice or mice 
treated with anti-NKG2D mAb were i.v. injected with 2 × 105 PFU 
of indicated viruses. Titers in the lungs of individual mice (circles) 3 d 
p.i. and median values (horizontal bars) are shown. The differences 
between the groups of untreated mice infected with ∆m138/fcr-1 
and WT or m138/fcr-1 revertant virus were signifi cant (P < 0.005). 
Depletion of NK cells and blockade of NKG2D resulted in a signifi cant 
increase (P < 0.005 for c and d; P < 0.025 for e) of ∆m138/fcr-1 
virus titers.
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of surface MULT-1, similar to the cells coinfected with 
MULT-1-VV and WT-VV. In contrast, coinfection with 
MULT-1–VV and VV expressing m145 or fcr-1 showed a 
similar extent of MULT-1 down-modulation. Analogous 
 results confi rmed that fcr-1 is suffi  cient to aff ect surface 
 expression of H60. The specifi c and autonomous eff ect of 
fcr-1 on MULT-1 as well as on H60 was further confi rmed 
after its transient coexpression with these NKG2D ligands in 
293 HEK cells (Fig. 2 b). Although cotransfection with a 
HCMV US2 plasmid preserved high levels of MULT-1 and 
H60, cotransfection of the m138/fcr-1 gene resulted in much 
lower surface densities of both NKG2D ligands. We con-
cluded that fcr-1 requires no other viral proteins for the 
down-modulation of MULT-1 and H60.
NKG2D-dependent early attenuation of 𝚫m138/fcr-1 
replication in vivo
We have previously found that MCMV lacking m138/fcr-1 is 
severely attenuated in vivo during the primary phase of infec-
tion (16) in which IgG does not contribute to the immune 
control (17). This already suggests an additional function of 
fcr-1, unrelated to its IgG-binding capacity. Therefore, we 
tested whether the attenuation of ∆m138/fcr-1 mutant is as 
the result of its increased susceptibility to NK cells in vivo. 
BALB/c mice were infected with ∆m138/fcr-1 virus or WT 
MCMV and the viral load in diff erent organs was determined 
3 d post-infection (p.i.). Injection of rabbit antiserum to 
asialo-GM1 (AGM1), which leads to the depletion of NK 
cells, restored the replication of ∆m138/fcr-1 to the same 
level as in WT control virus on day 3 p.i. (Fig. 2 c). Similar 
results were obtained when mice received an i.v. injection of 
MCMV-infected cells instead of infectious virus (Fig. 2 d). 
The mice infected with ∆m138/fcr-1 showed signifi cantly 
lower viral titers as compared with mice that received cells 
infected with m138 revertant virus RMS95.9. Importantly, 
injection of NKG2D-specifi c blocking antibodies rescued 
the titers of ∆m138/fcr-1 mutant to the WT level (Fig. 2 e). 
These data demonstrate that fcr-1 enhances MCMV replica-
tion in vivo in an NKG2D- and NK cell–dependent manner 
and reconcile the seemingly paradoxical fi nding of ∆m138/
fcr-1 MCMV attenuation in IgG-defi cient mice.
Identifi cation of Ig-like domains of the fcr-1 ectodomain 
down-modulating MULT-1 and H60
A detailed sequence alignment revealed the fcr-1 molecule 
to be phylogenetically congruent with host FcγR structures 
(unpublished data). fcr-1 is predicted to preserve three FcγR-
related putative IgSF-like domains Ig1, Ig2, and Ig3, which 
exhibit a low but still signifi cant sequence homology with 
IgSF domains of cellular FcγRs CD16/FcγRIII and CD32/
FcγRII, reaching 17% identity and 24% similarity, and are 
 adjacent to the top N-glycan–rich domain (13). To identify 
the domains involved in down-modulation of MULT-1 and 
H60, we constructed mutant viruses lacking either of three 
IgSF-like domains, as well as viruses possessing only one 
of them in conjunction with the stabilizing N-glycan–rich 
 domain (Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20060514/DC1). SVEC4-10 cells were in-
fected with either MCMV lacking m138/fcr-1, with m138/fcr-1-
revertant, WT, or with mutant MCMVs possessing truncated 
forms of Ig-like domains (Fig. 3). As expected, WT virus and 
the revertant caused the down-regulation of MULT-1 and 
Figure 3. The fcr-1 Ig1 domain is responsible for MULT-1 down-
modulation. SVEC4-10 cells infected for 22 h with 5 PFU per cell of 
 indicated viruses or left uninfected were stained with rat anti–MULT-1 
mAb or anti-H60 mAb. Irrelevant primary antibody was used as a negative 
control (thin line).
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H60, whereas the m138/fcr-1 negative mutant failed to inhibit 
their surface expression. The mutant lacking Ig1 domain also 
lost its ability to regulate both ligands. The MULT-1, but not 
H60, regulating function was preserved in mutants lacking 
either the middle or the membrane-proximal third Ig domain. 
The absence of the Ig3 domain decreased the ability of fcr-1 
to down-modulate MULT-1 to a certain extent. Because the 
Ig3 as well as the Ig2 domain had no eff ect on MULT-1 when 
expressed in isolation (Fig. 3), the intermediate MULT-1 
 phenotype may be as a result of steric constraints on the  activity 
of the Ig1 domain caused by the alteration in the  protein 
 structure. The infl uence of the Ig1 domain on MULT-1 was 
confi rmed by the expression of m138/fcr-1 mutants in HEK 
293T cells cotransfected with MULT-1. In contrast, the Ig1 do-
main alone failed to decrease surface expression of H60. When 
fcr-1 mutants lacking the cytoplasmic or  transmembrane part 
of the molecule were analyzed, membrane insertion, but not 
the cytoplasmic tail of fcr-1, was identifi ed as  being essential 
for MULT-1 modulation (Fig. S2, available at http://www.
jem.org/cgi/content/full/jem.20060514/DC1). Collectively, 
the data identifi ed the Ig1 domain of the fcr-1 ectodomain to 
be necessary to down-regulate MULT-1 and even suffi  cient 
when expressed in the absence of Ig2 and Ig3. In contrast, 
H60 down-regulation required the preserved composition of 
the complete fcr-1 ectodomain, indicating a diff erent mode of 
interaction with fcr-1.
m138/fcr-1 constitutes a surface resident Fc𝛄R
The fi nding that fcr-1 down-regulates NKG2D ligands 
from the cell surface prompted us to reevaluate the surface 
 disposition of the molecule to qualify its FcγR function. 
 Fibroblasts were infected with WT MCMV and ∆m138/fcr-1 
mutant for 14 h before staining with mouse IgG-Fc  fragments 
on the cell surface and intracellularly (Fig. 4 a). Fc-binding 
activity was readily detectable both on the cell surface and 
inside of the WT-infected, but not in the ∆m138/fcr-1–
 infected, cells. fcr-1 molecule thus specifi cally binds IgG-Fc 
on the cell surface, constituting a true vFcγR.
fcr-1 interferes with the recycling of surface MULT-1 
and leads to its subsequent degradation in lysosomes
MULT-1 maturation in MCMV-infected cells is not 
 altered before it reaches the medial-Golgi compartment 
(12).  Moreover, MULT-1 is able to reach the trans-Golgi 
 compartment (TGN) in infected cells (Fig. S3, available at 
http://www.jem.org/cgi/content/full/jem.20060514/DC1). 
We therefore studied the fate of surface resident MULT-1 
by a modifi ed uptake assay (18). By tagging MULT-1 with 
specifi c mAb in uninfected cells, we observed that although 
MULT-1 colocalizes with internalized transferrin in vesicles 
(Fig. 4 b), it also persists on the cell surface for a prolonged 
period of time (Fig. 5 a, fi rst column), implying vesicular 
recycling. Therefore, we tested whether fcr-1 could down-
modulate surface MULT-1 by interfering with the recycling 
pathway. In contrast with stable expression of surface resident 
MULT-1 on uninfected cells, MCMV infection causes a rapid 
fcr-1–dependent down-modulation, whereas the virus lack-
ing m138/fcr-1 gene cannot aff ect the stability of surface resi-
dent MULT-1 (Fig. 5 a). The lack of down-modulation of 
CD29 (β1 integrin) as detected by an isotype-matched mAb 
demonstrated the fcr-1 specifi city for MULT-1 (Fig. 5 c). 
Because fcr-1 is known to bind the Fc fragment of the IgG, as 
a further control we used F(ab)2 fragments of anti–MULT-1 
mAb in the uptake assay and obtained the same results 
of fcr-1–dependent MULT-1 down-regulation. Next, we 
determined the fate of MULT-1 molecules and observed that 
MULT-1 is not only down-modulated from the cell surface, 
but also degraded in the presence of fcr-1 (Fig. 5 b). The fcr-1 
eff ect on MULT-1 was completely abolished by imipramine, 
which inhibits the AP2-mediated clathrin pathway known
to be involved in the recycling of transferrin receptor. 
 Ammonium chloride and leupeptin, inhibitors of the lyso-
somal degradation pathway, prevented MULT-1 degradation, 
whereas specifi c inhibitors of the proteasome, lactacistine, 
and epoxomicin, had no eff ect (unpublished data). The fl ow 
 cytometry data provided the evidence of imipramine  rescuing 
MULT-1 on the surface of infected cell (Fig. S4, available at 
http://www.jem.org/cgi/content/full/jem.20060514/DC1), 
whereas the downstream inhibitors of MULT-1 degrada-
tion could not prevent MULT-1 down-regulation from 
the plasma membrane. Altogether, the data confi rmed that 
fcr-1 is responsible for the interference with the recycling 
of the surface portion of MULT-1, leading to its subsequent 
Figure 4. fcr-1 is readily detected on the cell surface of MCMV-
infected cells and surface resident MULT-1 is rapidly recycling. 
(a) (10)1 cells were mock infected or infected with 5 PFU per cell of WT 
MCMV or ∆m138/fcr-1. 15 h p.i., the cells were surface stained and intra-
cellularly stained with mouse IgG Fc fragment and Cy5-labeled anti–
mouse IgG. (b) Confocal analysis was performed on MULT-1–3T3 cells 
Ab-tagged for surface MULT-1 (red) as described for the uptake assay. 
Transferrin-FITC (green) was added in parallel with anti–MULT-1 mAb.
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lysosomal degradation. We did not observe a  similar recycling 
process of H60 (unpublished data), the fcr-1 eff ect upon which 
involves also other domains of fcr-1 and is apparently based on 
another mechanism that requires further studies.
Concluding remarks
This work identifi es an MCMV antagonist of NKG2D-
 mediated NK cell responses, the existence of which was pre-
dicted by the studies on NKG2D inhibitors m145 (12) and 
m155 (8, 10). Surprisingly, the previously described MCMV 
FcγR, fcr-1, turned out to act as a strong and autonomous 
regulator of two NKG2D ligands, MULT-1 and H60. This 
underlines the enormous selective pressure of NK cell  control 
on the virus to subvert NKG2D receptor triggering. The 
modular composition of the fcr-1 molecule may allow the 
protein to approach structurally diverse targets. Indeed, fcr-1 
is able to down-modulate at least two additional immune 
 receptor ligands involved in the activation of T cell responses 
(unpublished data and Mintern, J.D., personal  communication). 
The same N-terminal part of the fcr-1 ectodomain, Ig1, 
which is suffi  cient for MULT-1 function, is also needed to 
complex with the Fc part of IgG. In fact, soluble Fc  fragments 
of IgG are able to inhibit fcr-1–mediated down-modulation 
of MULT-1, presumably by competing for the binding 
to the same fcr-1 domain (unpublished data). Evidence is 
 provided that fcr-1 interferes with the clathrin-dependent 
endocytosis of MULT-1, leading to its subsequent lysosomal 
degradation. Altogether, these remarkable properties of fcr-1 
explain the prominent functional roles of this vFcγR in vivo 
as suggested by the dramatic, IgG-independent attenuation of 
MCMV mutants lacking this gene (16).
MATERIALS AND METHODS
Cells. CV-1 (CCL-70; American Type Culture Collection); SVEC4-10 
(CRL-2181; American Type Culture Collection); NIH3T3 (CRL1658; 
American Type Culture Collection); HEK 293T (CRL-11268; American 
Type Culture Collection); B12 fi broblasts (10); (10)1 fi broblasts (19); H60-
3T3 (H60-transfected NIH3T3 cells; reference 10); and MULT-1–3T3 
(MULT-1–transfected NIH3T3 cells; reference 12) were cultivated in 
DMEM supplemented with 10% FCS. Mouse embryonic fi broblasts (MEFs) 
prepared from BALB/c mice were cultivated in MEM supplemented with 
3% FCS. HEK 293T cells were cotransfected with pcDNA3.1–MULT-1 
and pIRES-US2-EGFP or pIRES2-m138-EGFP in a ration of 1:6, using 
Polyfect (QIAGEN) according to the manufacturer’s instructions.
Viruses. A bacterial artifi cial chromosome (BAC)-derived MCMV, 
MW97.01, has previously been shown to be biologically equivalent to the 
MCMV Smith strain (VR-194 [reaccessioned as VR-1399]; American Type 
Figure 5. fcr-1 targets surface resident MULT-1 for lysosomal 
degradation. SVEC4-10 (a and c) or MULT-1–3T3 (b) cells either mock 
infected or infected with 4 PFU per cell of WT MCMV or ∆m138/fcr-1 
were Ab-tagged for surface proteins. Cells were treated as described 
for uptake assay with rat anti–MULT-1 mAb (IgG2a). In addition, 
F(ab)2fragments of anti–MULT-1 mAb or rat anti-CD29 mAb (IgG2a) 
were used (c). After incubation for the indicated time periods, the cells 
were analyzed for the surface proteins (a and c). MULT-1 expression was 
examined after treatment with different inhibitors as described in the 
confocal microscopy section (b).
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Culture Collection) and is here referred as WT MCMV (20). The  generation 
of the following recombinant MCMV mutants was described elsewhere: 
MCMV-∆m145 (12); MCMV-∆6 (m144-m158), MCMV-∆7 (m159-m170) 
(21); MCMV-∆m152, MCMV-∆m06∆m152 (22); and the ∆m138/fcr-1 
 virus (∆MC95.15) and its revertant MCMV-m138Rev (RMS95.9) (16). 
MCMV mutagenesis and the construction of MCMV ∆A1 and m138/fcr-1 
mutants are described in detail in the online supplemental material.
Recombinant VV expressing either MULT-1 (MULT-1–VV), H60 
(H60-VV), MCMV m145 (m145-VV), MCMV m155 (m155-VV), or 
MCMV m138/fcr-1 (m138-VV) were described previously (12, 15) (8, 10).
Uptake assay. To chase the surface resident proteins, a modifi ed uptake 
 assay was used (18). The surface portion of referred proteins was tagged with 
specifi c mAb in PBS for 30 min on ice. MULT-1 was tagged with rat anti–
MULT-1 mAb (12) and in some experiments, F(ab)2 fragments of anti–
MULT-1 mAb were used that were prepared by pepsin digestion and 
separated from Fc fragments and IgG by the use of HiTrap Protein G HP 
column (GE Healthcare). CD29 was tagged with rat anti–mouse CD29 
mAb (BD Biosciences) of the same rat IgG2a isotype as determined for the 
rat anti–MULT-1 mAb. The excess of mAb was washed, the cells were 
 returned to 37°C, and the antibody-tagged protein was chased for a given 
period of time. For fl ow cytometry analysis, cells were harvested, washed in 
PBS, and PE-labeled goat anti–rat IgG was added for 25 min on ice. For 
confocal analysis, cells were washed in PBS, fi xed, and permeabilized as 
 described in section confocal analysis. The TRITC-labeled goat anti–rat IgG 
was added for an additional 40 min at room temperature. Cells were 
 uninfected or infected with 4 PFU of indicated viruses. The inhibitors of 
diff erent cellular pathways were used at the following concentrations: 
 imipramine (40 μg/ml, Sigma-Aldrich), NH4Cl (40 mM; Sigma-Aldrich), 
and leupeptin (75 μg/ml, Sigma-Aldrich). The cells were stained in parallel 
with irrelevant primary mAb followed by fl uorescence-labeled secondary Ab.
Flow cytometry. SVEC4-10, H60-3T3, MULT-1-3T3, (10)1, NIH3T3, 
and B12 cells were mock treated or infected with MCMV for indicated 
 periods of time, harvested by trypsinization or ethylenediaminetetraacetic 
acid (EDTA), and washed in PBS supplemented with 1% BSA and 0.1% 
NaN3. The cells were incubated for 25 min on ice with rat anti–MULT-1 
mAb (12), F(ab)2 fragments of anti–MULT-1 mAb, rat anti–RAE-1αβγ 
mAb CX1 (9), rat anti-H60 mAb (R&D Systems), and mouse anti-Kd mAb 
MA-215. After washing the cells, the binding of fi rst antibodies was  visualized 
by the addition of PE-labeled goat anti–rat IgG (Caltag Laboratories) 
or  biotinylated anti–rat IgG (Jackson ImmunoResearch Laboratories) fol-
lowed by PE-labeled streptavidin (Becton Dickinson). The fi rst antibodies of 
mouse origin were visualized with FITC-labeled goat anti–mouse Ig (BD 
 Biosciences). The binding of mouse IgG-Fc fragments (Rockland Immuno-
chemicals) to infected and uninfected cells was visualized with anti–mouse 
IgG-Cy5 (Dianova). The detection of NKG2D ligands on the surface of 
 uninfected and infected cells was performed by PE-NKG2D tetramers (8). 
For surface staining, the cells were labeled directly after harvesting; for 
 intracellular staining, cells were fi xed in paraformaldehyde and  permeabilized 
in 0.1% saponin before incubation with antibodies. Cells infected with 
 indicated viruses were discriminated by intracellular staining with mouse 
mAb CROMA 229, which recognizes MCMV gp48 antigen; mouse mAb 
CROMA 101, which recognizes MCMV pp89 antigen; or by surface 
 staining with mouse mAb 38–14-8s (anti-H-2Lq). In some experiments, 
GFP viruses were used or an infection dose of 4 PFU per cell was used to 
achieve an infection rate of >95% of cells.
CV-1 cells were mock treated or infected with VV by a multiplicity of 
infection PFU/cell of 4, harvested 16 h after infection, and stained with rat 
anti–MULT-1 mAb (12), rat anti-H60 mAb clone 205326 (provided by J.P. 
Houchins, R&D Systems, Minneapolis, MN) or rat IgG2a isotype control, 
followed by PE-labeled goat anti–rat IgG (Caltag Laboratories).
HEK 293T cell transfectants were harvested 24 h after transfection, 
washed in PBS supplemented with 2.5% (vol/vol) FCS and 0.05% (wt/vol) 
NaN3, (FACS-PBS), and subsequently incubated with rat anti–MULT-1 mAb, 
followed by biotinylated anti–rat IgG and PE-labeled streptavidin, each for 
25 min on ice with three washing steps after incubations.  Transfected cells 
were identifi ed by gating on EGFP-positive cells. The cells were stained 
in parallel with irrelevant primary mAb followed by fl uorescence-labeled 
secondary Ab. All samples were analyzed with a Becton Dickinson FACScan 
or Becton Dickinson FACSCalibur.
Confocal analysis. MULT-1–3T3 transfectants grown on glass coverslips 
were infected with 4 PFU per cell of WT-MCMV, ∆m138/fcr-1, or left 
 uninfected. The cells were washed in PBS, fi xed with 2.5% (wt/vol) 
 paraformaldehyde for 20 min at room temperature, and permeabilized using 
a 5-min incubation in 0.1% (wt/vol) Triton X-100. For visualization of 
MULT-1, rat anti–MULT-1 mAb (12) was used either as described for 
the uptake assay, or for 40 min in PBS at room temperature after the 
 permeabilization, both followed by goat anti–rat IgG F(ab)2 TRITC-labeled 
 secondary antibody (Santa Cruz Biotechnology, Inc.). The unspecifi c 
 binding was blocked with 0.2% (wt/vol) fi sh skin gelatin. Cells incubated 
with secondary antibody upon binding to irrelevant rat IgG2a antibodies 
were used as a  negative control. FITC-labeled transferrin (Sigma-Aldrich) 
was used in the uptake assay in parallel with anti–MULT-1 mAb as a marker 
of recycling pathway. The rabbit anti-Rab6 (Santa Cruz Biotechnology, 
Inc.) was used for the visualization of the medial- and trans-Golgi apparatus, 
followed by FITC-labeled secondary antibodies obtained from Santa Cruz 
Biotechnology, Inc. All samples were analyzed with Olympus FV300 confocal 
laser scanning microscope.
Mice. BALB/c mice (H-2d) were housed and bred under specifi c pathogen-
free conditions at the Central Animal Facility of the Faculty of Medicine 
University of Rijeka, in accordance with the general principles contained 
in the Guide for the Care and Use of Laboratory Animals (National 
 Academies Press). The Ethical Committee at the Faculty of Medicine of the 
University of Rijeka approved all animal experiments. 6–8-wk-old female 
mice were used.
Infection conditions, detection of infectious MCMV in tissues, and 
statistical evaluation. Mice were injected i.v. with 2 × 105 PFU of tissue 
culture–grown WT MCMV or recombinant virus in 500 μl of diluent. The 
mice were also infected by i.v. inoculation of 104 BALB/c MEF cells  infected 
for 12 h with 2 PFU of indicated viruses (8). Organs were collected at 3 d 
p.i. and viral titers were determined by a standard plaque-forming assay (23). 
The statistical signifi cance of the diff erence between experimental groups 
was determined by the Mann-Whitney exact rank test. Viral titers (from 
groups x and y) were considered signifi cantly diff erent for p-values (x versus y) 
of <0.05 (one-sided).
Depletion of NK cells. The depletion of NK cells was performed by i.p. 
injection of rabbit antibodies to asialo-GM1 (Wako Chemicals) at the dose 
of 25 μl in 500 μl of diluent, 24 h before infection. NKG2D was blocked 
by i.p. injection of blocking anti-NKG2D mAb (R&D Systems) at a dose of 
100 μg/mouse in 500 μl of diluent, 24 h before infection.
Online supplemental material. MCMV mutagenesis and the construc-
tion of MCMV m138/fcr-1 mutants are described in detail in Fig. S1. 
Fig. S2 demonstrates the transmembrane domain of fcr-1, but not the 
 cytoplasmic tail to be essential for MULT-1 regulation. Fig. S3 presents 
the  colocalization of MULT-1 intracellular fraction with the Rab6 as the 
marker of medial- and trans-Golgi apparatus in the uninfected and WT 
MCMV-infected cells. The fl ow cytometry data (Fig. S4) show that the 
inhibitors of lysosomal degradation in contrast with the inhibitor of clathrin 
endocytosis cannot rescue the surface expression of MULT-1 in MCMV-
infected cells. Online supplemental fi gures are available at http://www.jem.
org/cgi/content/full/jem.20060514/DC1.
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